粒子治疗市场－全球产业规模、份额、趋势、机会、预测：按类型、系统、应用、癌症类型、地区和竞争格局划分，2021-2031年

全球粒子束治疗市场预计将从 2025 年的 9.9921 亿美元成长到 2031 年的 13.6293 亿美元，复合年增长率为 5.31%。

这种特殊的体外放射治疗利用质子和重离子等带电粒子，透过在布拉格峰处释放最大能量，精准地靶向恶性肿瘤。市场成长的主要驱动力是癌症发生率的上升以及临床上需要最大限度地减少敏感解剖区域的辐射中毒，这使得人们对这种疗法的需求超过了传统的基于光子的疗法。此外，越来越多的临床证据表明，这种疗法在儿童和复杂成人病例中具有更优的患者疗效，这也进一步推动了此类治疗系统的广泛应用。

然而，该领域的发展仍面临许多障碍，包括设施建设和维护需要大量资金投入，以及保险报销政策不一致可能导致患者就医受阻。这些财务障碍往往限制了营运规模，尤其是在註重成本的医疗环境中。儘管有这些障碍，成熟市场的需求依然强劲。例如，根据美国质子治疗协会的数据，2024年美国总合18,202名患者接受了质子治疗。

市场驱动因素

全球癌症和肿瘤疾病发生率的不断上升凸显了精准放射治疗性介入的迫切性，也是全球粒子束治疗市场发展的主要驱动力。随着恶性肿瘤发生率的上升，医疗机构不得不采用质子治疗等先进方法，以最大限度地控制肿瘤，同时最大限度地减少对重要器官的非靶向辐射暴露。对于传统光子治疗长期毒性风险较高的复杂病例，这项要求尤其重要。为了强调这一日益沉重的负担，国际癌症研究机构（IARC）在其2024年2月发布的全球癌症负担新闻稿中预测，到2050年，全球新增癌症病例将超过3500万例，比2022年增长77%。

同时，紧凑型单腔质子治疗系统的技术进步降低了医疗机构的投资门槛，并加速了治疗的普及。该领域正从大规模多腔设施转向模组化、节省面积的解决方案。这使得医院能够将粒子治疗整合到现有基础设施中，从而降低财务风险。这种向经济高效技术的转变已透过商业性成功得到证实。根据Mevion Medical Systems公司2024年9月发布的新闻稿，其紧凑型质子治疗解决方案在过去五年中已占据美国市场60%的份额。为了佐证此类扩充性创新技术的重要性，美国癌症协会于2024年1月发布的《2024年癌症事实与数据》报告预测，美国每年新增癌症病例数将首次超过200万例。

市场挑战

医疗领域保险报销政策的不一致严重阻碍了全球粒子束治疗市场的发展。儘管粒子束治疗具有明显的临床优势，但不确定的支付模式常常削弱了这些高成本设施的营运经济可行性。这是因为私人保险公司和政府支付机构将质子束治疗在许多适应症中归类为实验性疗法，或设定了严格的预先核准要求，导致理赔被拒和付款延迟。这种收入预测的困难使得医疗机构难以收回建设设施所需的大量资本投资，从而阻碍了投资者的参与，并抑制了新兴市场新中心的建设。

严峻的经济状况因现有支付结构的下行压力而进一步恶化。据美国国家质子治疗协会称，美国医疗保险和医疗补助服务中心提案，自2024年起，将5级放射治疗程序的报销率降低1.5%。此类关键治疗程序报销率的降低将直接影响现有机构的营运利润率。因此，这种财务波动将迫使医疗机构限制患者入院人数或暂停扩张计划，直接限制市场的整体扩充性和可及性。

市场趋势

超高剂量FLASH粒子疗法的出现正在改变市场格局，它能够在通常不到一秒的时间内实现超高剂量率的辐射输送。这项技术模式转移利用了“FLASH效应”，在严格控制肿瘤的同时显着降低对健康组织的毒性，克服了传统放射治疗通讯协定的许多局限性。该领域的研究正在迅速发展，大量资金投入研发，领先的医疗机构正努力将临床前研究成果转化为临床应用。例如，宾州大学医学院在2024年5月发表的一篇报导《FLASH：迈向超快新型放射疗法的一步》中提到，研究人员获得了美国国立卫生研究院（NIH）1230万美元的津贴，用于研究质子束FLASH疗法的潜力及其保护癌症患者健康组织的能力。

同时，笔射束扫描（PBS）技术的广泛应用正逐渐成为业界标准，取代被动散射方法，并提升治疗的适用性。 PBS技术能够实现强度调节质子治疗（IMPT），使临床医生能够以布拉格峰的精确度逐点「绘製」肿瘤。这对于治疗位于重要结构附近的复杂恶性肿瘤至关重要。这项技术优势在大型商业合约中得到了充分体现，在这些合约中，PBS功能是新建医疗设施的首要条件。例如，根据2024年5月《影像技术新闻》的报道，IBA与耶鲁纽黑文医疗中心和哈特福德医疗保健中心签订的合约（价值4,000万至5,000万美元）明确包含了配备笔射束扫描技术的系统，这便体现了市场趋势。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球粒子治疗市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依类型（质子束疗法、重离子束疗法）
  • 系统类型（多房间系统、单房间系统）
  • 依应用领域（治疗用途、研究用途）
  • 癌症类型（儿童癌症、肺癌、乳癌、其他癌症）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美粒子治疗市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲粒子治疗市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区粒子疗法市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲粒子疗法市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲粒子疗法市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章 全球粒子治疗市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Advanced Oncotherapy plc
• Danfysik A/S
• Hitachi, Ltd
• IBA LLC
• Mevion Medical Systems, Inc.
• Optivus Proton Therapy, Inc.
• ProTom International, Inc.
• Provision Healthcare Ltd
• Sumitomo Heavy Industries, Ltd.
• Varian Medical Systems, Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Particle Therapy Market is projected to expand from USD 999.21 Million in 2025 to USD 1362.93 Million by 2031, reflecting a compound annual growth rate of 5.31%. This specialized form of external beam radiotherapy utilizes charged particles, including protons and heavy ions, to target malignancies with high precision by depositing maximal energy at the Bragg peak. The market is primarily propelled by the rising incidence of cancer and the clinical imperative to minimize radiation toxicity in sensitive anatomical areas, which drives demand for this modality over traditional photon-based treatments. Additionally, the growing body of clinical evidence demonstrating superior patient outcomes in pediatric and complex adult cases continues to support the broader adoption of these therapeutic systems.

However, the growth of this sector faces significant hurdles due to the high capital investments required for facility construction and maintenance, as well as inconsistent insurance reimbursement policies that can impede patient access. These financial barriers often limit operational scalability, particularly within cost-sensitive healthcare environments. Despite these obstacles, demand remains strong in established markets; for instance, according to the National Association for Proton Therapy, a total of 18,202 patients received proton therapy treatment across the United States in 2024.

Market Driver

The escalating global prevalence of cancer and oncological disorders serves as a fundamental catalyst for the Global Particle Therapy Market, creating an urgent need for precise radiotherapeutic interventions. As malignancy rates climb, healthcare providers are compelled to adopt advanced modalities like proton therapy that maximize tumor control while minimizing off-target radiation to critical organs, a requirement that is particularly acute for complex cases where conventional photon therapy carries high risks of long-term toxicity. Highlighting this increasing burden, the International Agency for Research on Cancer (IARC) predicted in a February 2024 press release regarding the 'Global Cancer Burden' that new cancer cases globally will rise to over 35 million by 2050, representing a 77% increase from 2022 levels.

Concurrently, technological advancements in compact and single-room proton therapy systems are revolutionizing accessibility by lowering capital barriers for medical institutions. The sector is transitioning from massive multi-room facilities toward modular, smaller-footprint solutions that allow hospitals to integrate particle therapy into existing infrastructures with reduced financial risk. This shift toward cost-efficient technology is demonstrated by commercial traction; according to a September 2024 press release by Mevion Medical Systems, their compact proton therapy solutions captured 60% of the announced United States market over the past five years. Underscoring the critical necessity for such scalable innovations, the American Cancer Society's 'Cancer Facts & Figures 2024' report from January 2024 projects that the United States is expected to surpass 2 million new cancer cases in a single year for the first time.

Market Challenge

Inconsistent insurance reimbursement policies within the healthcare sector constitute a substantial barrier hampering the growth of the Global Particle Therapy Market. Although the clinical advantages of particle therapy are evident, the financial viability of operating these high-cost facilities is frequently undermined by uncertain payment models, as private insurers and government payers often categorize proton therapy as experimental for many indications or enforce strict prior authorization requirements that lead to claim denials and payment delays. This unpredictability in revenue generation makes it difficult for medical institutions to recover the massive capital expenditures required for facility construction, thereby discouraging investors and stalling the development of new centers in emerging markets.

This challenging economic landscape is further intensified by downward pressure on established payment structures. According to the National Association for Proton Therapy, in 2024, the Centers for Medicare & Medicaid Services proposed a 1.5% payment rate decrease for codes mapping to Level 5 Radiation Therapy procedures. Such reductions in reimbursement rates for critical treatment codes directly impact the operational margins of existing facilities. Consequently, this financial volatility forces providers to limit patient intake or halt expansion plans, directly restricting the market's overall scalability and accessibility.

Market Trends

The emergence of Ultra-High Dose FLASH Particle Therapy is transforming the market by enabling the delivery of radiation at ultra-high dose rates, typically in less than one second. This technological paradigm shift leverages the "FLASH effect" to significantly reduce toxicity to healthy tissues while maintaining rigorous tumor control, thereby addressing a critical limitation of conventional radiotherapy protocols. Research momentum in this domain is accelerating rapidly as leading medical institutions seek to translate preclinical success into clinical applications, attracting substantial funding for development. Illustrating this commitment to innovation, according to Penn Medicine, May 2024, in the 'FLASH forward to an ultra-fast new form of radiation' article, researchers secured a 12.3 million US dollar NIH grant to study proton FLASH therapy and its potential to spare normal tissue in cancer patients.

Simultaneously, the widespread adoption of Pencil Beam Scanning (PBS) technology is becoming the industry standard, progressively replacing passive scattering methods to enhance treatment conformity. PBS enables Intensity-Modulated Proton Therapy (IMPT), allowing clinicians to "paint" tumors spot-by-spot with Bragg peak accuracy, which is essential for treating complex malignancies near critical structures. This technological dominance is increasingly reflected in major commercial contracts where PBS capabilities are a primary requirement for new facility installations. Evidencing this market preference, according to Imaging Technology News, May 2024, in an article regarding IBA signing a contract with Yale New Haven Health and Hartford HealthCare, a contract valued between 40 and 50 million US dollars was signed for a system specifically equipped with Pencil Beam Scanning technology.

Key Market Players

• Advanced Oncotherapy plc
• Danfysik A/S
• Hitachi, Ltd
• IBA LLC
• Mevion Medical Systems, Inc.
• Optivus Proton Therapy, Inc.
• ProTom International, Inc.
• Provision Healthcare Ltd
• Sumitomo Heavy Industries, Ltd.
• Varian Medical Systems, Inc.

Report Scope

In this report, the Global Particle Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Particle Therapy Market, By Type

• Proton therapy
• Heavy-ion therapy

Particle Therapy Market, By System

• Multi-room systems
• Single-room systems

Particle Therapy Market, By Application

• Treatment application
• Research application

Particle Therapy Market, By Cancer-type

• Pediatric Cancer
• Lung Cancer
• Breast cancer
• Other cancers

Particle Therapy Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Particle Therapy Market.

Available Customizations:

Global Particle Therapy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Particle Therapy Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Proton therapy, Heavy-ion therapy)
  • 5.2.2. By System (Multi-room systems, Single-room systems)
  • 5.2.3. By Application (Treatment application, Research application)
  • 5.2.4. By Cancer-type (Pediatric Cancer, Lung Cancer, Breast cancer, Other cancers)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Particle Therapy Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By System
  • 6.2.3. By Application
  • 6.2.4. By Cancer-type
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Particle Therapy Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By System
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By Cancer-type
  • 6.3.2. Canada Particle Therapy Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By System
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By Cancer-type
  • 6.3.3. Mexico Particle Therapy Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By System
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By Cancer-type

7. Europe Particle Therapy Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By System
  • 7.2.3. By Application
  • 7.2.4. By Cancer-type
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Particle Therapy Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By System
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By Cancer-type
  • 7.3.2. France Particle Therapy Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By System
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By Cancer-type
  • 7.3.3. United Kingdom Particle Therapy Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By System
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By Cancer-type
  • 7.3.4. Italy Particle Therapy Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By System
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By Cancer-type
  • 7.3.5. Spain Particle Therapy Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By System
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By Cancer-type

8. Asia Pacific Particle Therapy Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By System
  • 8.2.3. By Application
  • 8.2.4. By Cancer-type
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Particle Therapy Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By System
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By Cancer-type
  • 8.3.2. India Particle Therapy Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By System
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By Cancer-type
  • 8.3.3. Japan Particle Therapy Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By System
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By Cancer-type
  • 8.3.4. South Korea Particle Therapy Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By System
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By Cancer-type
  • 8.3.5. Australia Particle Therapy Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By System
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By Cancer-type

9. Middle East & Africa Particle Therapy Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By System
  • 9.2.3. By Application
  • 9.2.4. By Cancer-type
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Particle Therapy Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By System
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By Cancer-type
  • 9.3.2. UAE Particle Therapy Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By System
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By Cancer-type
  • 9.3.3. South Africa Particle Therapy Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By System
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By Cancer-type

10. South America Particle Therapy Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By System
  • 10.2.3. By Application
  • 10.2.4. By Cancer-type
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Particle Therapy Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By System
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By Cancer-type
  • 10.3.2. Colombia Particle Therapy Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By System
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By Cancer-type
  • 10.3.3. Argentina Particle Therapy Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By System
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By Cancer-type

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Particle Therapy Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Advanced Oncotherapy plc
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Danfysik A/S
• 15.3. Hitachi, Ltd
• 15.4. IBA LLC
• 15.5. Mevion Medical Systems, Inc.
• 15.6. Optivus Proton Therapy, Inc.
• 15.7. ProTom International, Inc.
• 15.8. Provision Healthcare Ltd
• 15.9. Sumitomo Heavy Industries, Ltd.
• 15.10. Varian Medical Systems, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer